MASH, or steatohepatitis associated with metabolic dysfunction, affects nearly 20% of the world's adult population. Researchers have discovered two forms of MASH: one genetic and the other linked to metabolic disorders, which could change its management.
MASH, formerly known as NASH (Non-Alcoholic Steatohepatitis), progresses from metabolic steatosis to fibrosis, cirrhosis, and potentially liver cancer. Symptoms and progression vary among patients.
A team coordinated by Inserm (the French National Institute of Health and Medical Research) identified two high-risk patient profiles by analyzing data from 1,800 patients: one with elevated triglyceride and HbA1c levels, and the other with abnormal levels of the liver enzyme ALT. The first group has cardiometabolic MASH, while the second develops genetic MASH.
The two forms have different biological mechanisms and clinical progressions. An application already exists that can identify the type of MASH a patient has, helping to predict the progression of the disease and to adapt the treatment.
 Frank Verain
|
09/12/2024 | 
| 
Anglais
Arabic
Deutsch
Français
Español
Italien
Português
Russian